Sarah Hillman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sarah Hillman has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Mark David Kilby
University of Birmingham, Birmingham, UK
9 shared publications - Joanne Parsons
Centre for Evidence and Implementation Science, Health Services Management Centre, School of Social Policy and Society, College of Social Sciences, University of Birmingham, Birmingham, UK
5 shared publications - Becky MacGregor
Department of Applied Health Sciences, School of Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK
4 shared publications - Debra Bick
Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, United Kingdom
4 shared publications - Jeremy Dale
University of Warwick
4 shared publications Mark D. Kilby
4 shared publications
Latest Publications
- Open Access
How healthcare professionals manage uncertainty around hormone replacement therapy (dis-)continuation: the TAPER qualitative Study
Many women experience menopausal symptoms after stopping hormone replacement therapy (HRT). An evidence gap remains regarding how women and healthcare professionals (HCPs) make decisions about discontinuing and restarting HRT. Aim: To explore experiences of HCPs that support women when they discontinue and restart HRT. Design and setting: Qualitative study with HCPs working in NHS primary care. Method: * The model describes HCPs’ experiences of supporting women to discontinue HRT as an iterative process characterised by uncertainty. Discussions about discontinuation were commonly prompted by changes in clinical risk or annual HRT review, but decisions about whether and when to stop also depended on women’s symptoms, side effects, life stage and readiness. HCPs described agreeing an individualised discontinuation strategy, providing support during the process, and reviewing women afterwards to consider alternative treatments or, where appropriate, restarting HRT. Semi-structured interviews with HCPs ( n = 15) conducted between October 2025 and March 2026. A preliminary coding template was created using the discussion guide as a framework. Each interview was then coded inductively against the template which developed iteratively. Team based discussion helped refine codes into themes and sub-themes, and a subsequent conceptual model was created. Results: The model describes HCPs’ experiences of supporting women to discontinue HRT as an iterative process characterised by uncertainty. Discussions about discontinuation were commonly prompted by changes in clinical risk or annual HRT review, but decisions about whether and when to stop also depended on women’s symptoms, side effects, life stage and readiness. HCPs described agreeing an individualised discontinuation strategy, providing support during the process, and reviewing women after discontinuation to consider alternative treatments or, where appropriate, restarting HRT. Conclusion: HCPs recognise the importance of readiness to discontinue and that decision making should be woman led, with HCP support, clear practice guidance and opportunities to revisit treatment. Further research is needed to support women weigh up their personalised risk and benefit of continuing/discontinuing and identify discontinuation strategies that limit resurgent symptoms. How this fits in: Hormone Replacement Therapy (HRT) use has increased substantially, but little is known about how healthcare professionals support women who are considering discontinuation. Existing guidance offers limited evidence on when and how HRT should be stopped or how best to manage recurrent symptoms. This study shows that discontinuation is an iterative, individualised process shaped by clinical risk, symptoms, life stage and women’s readiness to stop. Healthcare professionals would benefit from clearer guidance to support shared decision-making, follow-up and decisions about alternative treatment or restarting HRT.
Open AccessHow healthcare professionals manage uncertainty around hormone replacement therapy (dis-)continuation: the TAPER qualitative Study
Many women experience menopausal symptoms after stopping hormone replacement therapy (HRT). An evidence gap remains regarding how women and healthcare professionals (HCPs) make decisions about discontinuing and restarting HRT. Aim: To explore experiences of HCPs that support women when they discontinue and restart HRT. Design and setting: Qualitative study with HCPs working in NHS primary care. Method: * The model describes HCPs’ experiences of supporting women to discontinue HRT as an iterative process characterised by uncertainty. Discussions about discontinuation were commonly prompted by changes in clinical risk or annual HRT review, but decisions about whether and when to stop also depended on women’s symptoms, side effects, life stage and readiness. HCPs described agreeing an individualised discontinuation strategy, providing support during the process, and reviewing women afterwards to consider alternative treatments or, where appropriate, restarting HRT. Semi-structured interviews with HCPs ( n = 15) conducted between October 2025 and March 2026. A preliminary coding template was created using the discussion guide as a framework. Each interview was then coded inductively against the template which developed iteratively. Team based discussion helped refine codes into themes and sub-themes, and a subsequent conceptual model was created. Results: The model describes HCPs’ experiences of supporting women to discontinue HRT as an iterative process characterised by uncertainty. Discussions about discontinuation were commonly prompted by changes in clinical risk or annual HRT review, but decisions about whether and when to stop also depended on women’s symptoms, side effects, life stage and readiness. HCPs described agreeing an individualised discontinuation strategy, providing support during the process, and reviewing women after discontinuation to consider alternative treatments or, where appropriate, restarting HRT. Conclusion: HCPs recognise the importance of readiness to discontinue and that decision making should be woman led, with HCP support, clear practice guidance and opportunities to revisit treatment. Further research is needed to support women weigh up their personalised risk and benefit of continuing/discontinuing and identify discontinuation strategies that limit resurgent symptoms. How this fits in: Hormone Replacement Therapy (HRT) use has increased substantially, but little is known about how healthcare professionals support women who are considering discontinuation. Existing guidance offers limited evidence on when and how HRT should be stopped or how best to manage recurrent symptoms. This study shows that discontinuation is an iterative, individualised process shaped by clinical risk, symptoms, life stage and women’s readiness to stop. Healthcare professionals would benefit from clearer guidance to support shared decision-making, follow-up and decisions about alternative treatment or restarting HRT.
- 1 October 2026
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (771) , 438-440
Challenges in diagnosing and supporting those with premenstrual dysphoric disorder: opportunities for GPs
- 1 October 2026
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (771) , 438-440
Challenges in diagnosing and supporting those with premenstrual dysphoric disorder: opportunities for GPs
- Open Access
- 15 September 2026
- Published by Elsevier in SSRN Electronic Journal
TAPER Study Qualitative Analysis: How Women Balance Decision-making About Hormone Replacement Therapy (HRT) (dis)continuation
Background: The TAPER Study aims to explore what matters most to women and healthcare professionals (HCPs) when women consider stopping or restarting hormone replacement therapy (HRT). There is limited evidence to help women and their HCPs decide when and how to stop HRT. Stopping HRT often leads to the recurrence of menopausal symptoms which can negatively affect quality of life. Some women choose to restart HRT which can lead to a stop-restart cycle. This cycle may adversely affect women and increase healthcare use and costs. Methods: An exploratory qualitative study was conducted using semi-structured interviews. Twenty-six women aged 50-67 years were recruited through GP surgeries serving diverse populations and targeted social media adverts shared by community organisations. All interviews were all conducted remotely. Participants identified as Asian (n=4), Black (n=1) Mixed ethnicity (n=1) or white (n=20). Following informed consent, interviews were audio-recorded, transcribed and anonymised, and uploaded to NVivo 14 to support data management and analysis. Transcripts were analysed using codebook thematic analysis, using an iterative deductive-inductive approach in which the discussion guide was used to create the initial deductive coding template. Findings: Women made decisions to start, continue, stop, and/or restart HRT at different points, based on wider influences and assessments of their personal risk. These influences and risk assessments frequently intersected and included fear of, or actual, symptom recurrence; family experiences of menopause; perceived breast cancer risk; time spent using HRT; and considerations about whether they were post-menopausal. Women described uncertainty about the impact of stopping HRT and wanted more information about the likelihood and management of symptom recurrence following discontinuation. Interpretation: Women’s decision-making around HRT discontinuation and restarting was influenced by multiple, intersecting factors. Individualised support and clear information were needed to enable informed decision making and support women choosing to discontinue HRT.
- 15 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTAPER Study Qualitative Analysis: How Women Balance Decision-making About Hormone Replacement Therapy (HRT) (dis)continuation
Background: The TAPER Study aims to explore what matters most to women and healthcare professionals (HCPs) when women consider stopping or restarting hormone replacement therapy (HRT). There is limited evidence to help women and their HCPs decide when and how to stop HRT. Stopping HRT often leads to the recurrence of menopausal symptoms which can negatively affect quality of life. Some women choose to restart HRT which can lead to a stop-restart cycle. This cycle may adversely affect women and increase healthcare use and costs. Methods: An exploratory qualitative study was conducted using semi-structured interviews. Twenty-six women aged 50-67 years were recruited through GP surgeries serving diverse populations and targeted social media adverts shared by community organisations. All interviews were all conducted remotely. Participants identified as Asian (n=4), Black (n=1) Mixed ethnicity (n=1) or white (n=20). Following informed consent, interviews were audio-recorded, transcribed and anonymised, and uploaded to NVivo 14 to support data management and analysis. Transcripts were analysed using codebook thematic analysis, using an iterative deductive-inductive approach in which the discussion guide was used to create the initial deductive coding template. Findings: Women made decisions to start, continue, stop, and/or restart HRT at different points, based on wider influences and assessments of their personal risk. These influences and risk assessments frequently intersected and included fear of, or actual, symptom recurrence; family experiences of menopause; perceived breast cancer risk; time spent using HRT; and considerations about whether they were post-menopausal. Women described uncertainty about the impact of stopping HRT and wanted more information about the likelihood and management of symptom recurrence following discontinuation. Interpretation: Women’s decision-making around HRT discontinuation and restarting was influenced by multiple, intersecting factors. Individualised support and clear information were needed to enable informed decision making and support women choosing to discontinue HRT.
- 27 August 2026
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (770) , 426-428
Diagnosing in the dark: the childbirth-related post-traumatic stress disorder GP evidence gap
- 27 August 2026
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (770) , 426-428
Diagnosing in the dark: the childbirth-related post-traumatic stress disorder GP evidence gap
- 30 April 2026
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (766) , 202-204
Complex social needs and maternal postnatal care: what can primary care do?
- 30 April 2026
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (766) , 202-204
Complex social needs and maternal postnatal care: what can primary care do?
- Open Access
- 2 February 2026
- Published by Springer Nature
Discontinuation of hormone replacement therapy: TAPER study
- 2 February 2026
- Published by Springer Nature
Open AccessDiscontinuation of hormone replacement therapy: TAPER study
- Open Access
- 26 September 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Women's and Health Care Professionals' Experiences of Discontinuing Hormone Replacement Therapy (HRT): A Systematic Review
Background: Hormone Replacement Therapy (HRT) is used to manage menopausal symptoms, particularly vasomotor symptoms (VMS). HRT prescribing rates are rising, but most women will eventually discontinue.Objectives: To explore the experiences of women stopping HRT, why women restart HRT, and the HCPs advising them.Search Strategy: Embase, MEDLINE, CINAHL, Web of Science and PsycINFO were searched from 2000 to February 2024.Selection Criteria: Quantitative, qualitative and mixed methods studies assessing experiences of HRT discontinuation.Data Collection and Analysis: Quality was appraised using the Mixed Methods Appraisal Toolkit (MMAT). Data were narratively synthesised with weighted averages reported where possible.Main Results: Electronic database searches identified 9444 reports, with 74 reports from 69 studies, including 32 213 women and 2943 HCPs. Average age of the cohort analysed was 64.7 years. Discontinuation rate was 51.3%, with average HRT duration of 5.4 years. The majority of women abruptly stopped HRT (62.4%). Common reasons for discontinuation were HCP recommendation (31.2% of participants), fear about risks (26.0%) and preference for a natural approach (25.6%). Common symptoms upon discontinuation were unspecified menopausal symptoms (84.4%), sleep disturbances (51.9%) and VMS (45.4%). Four RCTs compared tapered and abrupt discontinuation; two found abrupt discontinuers had greater symptoms initially, but symptoms were comparable to those experienced by taperers after completion of the tapered withdrawal. Two RCTs found no difference. Average rate of restarting was 20.7%, with VMS commonly cited as a reason. HCPs cited health risks as a reason for discontinuation, and 91.6% recommended tapered discontinuation.Conclusions: This review provides insight into global HRT discontinuation experiences and highlights the need for future research to assess the best approach to discontinuation.
- 26 September 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Open AccessWomen's and Health Care Professionals' Experiences of Discontinuing Hormone Replacement Therapy (HRT): A Systematic Review
Background: Hormone Replacement Therapy (HRT) is used to manage menopausal symptoms, particularly vasomotor symptoms (VMS). HRT prescribing rates are rising, but most women will eventually discontinue.Objectives: To explore the experiences of women stopping HRT, why women restart HRT, and the HCPs advising them.Search Strategy: Embase, MEDLINE, CINAHL, Web of Science and PsycINFO were searched from 2000 to February 2024.Selection Criteria: Quantitative, qualitative and mixed methods studies assessing experiences of HRT discontinuation.Data Collection and Analysis: Quality was appraised using the Mixed Methods Appraisal Toolkit (MMAT). Data were narratively synthesised with weighted averages reported where possible.Main Results: Electronic database searches identified 9444 reports, with 74 reports from 69 studies, including 32 213 women and 2943 HCPs. Average age of the cohort analysed was 64.7 years. Discontinuation rate was 51.3%, with average HRT duration of 5.4 years. The majority of women abruptly stopped HRT (62.4%). Common reasons for discontinuation were HCP recommendation (31.2% of participants), fear about risks (26.0%) and preference for a natural approach (25.6%). Common symptoms upon discontinuation were unspecified menopausal symptoms (84.4%), sleep disturbances (51.9%) and VMS (45.4%). Four RCTs compared tapered and abrupt discontinuation; two found abrupt discontinuers had greater symptoms initially, but symptoms were comparable to those experienced by taperers after completion of the tapered withdrawal. Two RCTs found no difference. Average rate of restarting was 20.7%, with VMS commonly cited as a reason. HCPs cited health risks as a reason for discontinuation, and 91.6% recommended tapered discontinuation.Conclusions: This review provides insight into global HRT discontinuation experiences and highlights the need for future research to assess the best approach to discontinuation.
- Open Access
- 25 September 2025
- Published by BMJ in BMJ Medicine
- Vol. 4 (1) , e001349
Inequalities in hormone replacement therapy prescribing in UK primary care: population based cohort study
Objective: To quantify prescribing of hormone replacement therapy (HRT) in women aged 40-60 years by type of HRT and length of use, and to determine sociodemographic factors associated with receiving a HRT prescription. Design: Population based cohort study. Setting: QResearch database of primary care practices in England, 1 January 2013 to 13 July 2023, and patient electronic health records for prescribing information . Participants: 1 978 348 women aged 40-60 years at any time over a 10 year period. Main outcome measures: Overall uptake of two or more prescriptions of the same type of HRT in women of menopausal age, length of use, and association between ethnic group, deprivation, and geographical region and receiving a HRT prescription before and during the eight years since implementation of National Institute for Health and Care Excellence (NICE) guidance on the menopause in 2015 in the UK. Results: The cohort comprised 1 978 348 women with a mean age of 49.4 years, and 76.2% were white women. Overall, 379 911 (19.2%) women received two or more HRT prescriptions. Combination HRT formulations in one prescription were the most frequently prescribed (62.4% of those prescribed HRT), with 43.3% receiving oral and 26.3% transdermal formulations. Mean age at first prescription was 49.8 years. Rates for two or more prescriptions of HRT were higher in white women (22.6%) than in other ethnic groups, ranging from 8.9% in Caribbean women to 3.9% in black African women. Prescription rates decreased with increasing social deprivation, from 24.2% in the most affluent to 10.9% in the most deprived groups. London had lower prescription rates (11.7%) than other regions (all >19%). Multivariable Cox regression showed that non-white ethnic groups had significantly lower HRT prescription rates (hazard ratios 0.85-0.92, P<0.001), and each increase in social deprivation group was associated with lower HRT prescription rates (hazard ratio for the most deprived group 0.92, 95% confidence interval 0.92 to 0.93, P<0.001). Conclusions: This study identified differences in HRT prescribing in England based on ethnic group, socioeconomic status, and geographical location. White women and those in more affluent neighbourhoods were more likely to receive HRT than non-white women and those in more deprived areas. These findings suggest potential inequities that require further exploration.
- 25 September 2025
- Published by BMJ in BMJ Medicine
- Vol. 4 (1) , e001349
Open AccessInequalities in hormone replacement therapy prescribing in UK primary care: population based cohort study
Objective: To quantify prescribing of hormone replacement therapy (HRT) in women aged 40-60 years by type of HRT and length of use, and to determine sociodemographic factors associated with receiving a HRT prescription. Design: Population based cohort study. Setting: QResearch database of primary care practices in England, 1 January 2013 to 13 July 2023, and patient electronic health records for prescribing information . Participants: 1 978 348 women aged 40-60 years at any time over a 10 year period. Main outcome measures: Overall uptake of two or more prescriptions of the same type of HRT in women of menopausal age, length of use, and association between ethnic group, deprivation, and geographical region and receiving a HRT prescription before and during the eight years since implementation of National Institute for Health and Care Excellence (NICE) guidance on the menopause in 2015 in the UK. Results: The cohort comprised 1 978 348 women with a mean age of 49.4 years, and 76.2% were white women. Overall, 379 911 (19.2%) women received two or more HRT prescriptions. Combination HRT formulations in one prescription were the most frequently prescribed (62.4% of those prescribed HRT), with 43.3% receiving oral and 26.3% transdermal formulations. Mean age at first prescription was 49.8 years. Rates for two or more prescriptions of HRT were higher in white women (22.6%) than in other ethnic groups, ranging from 8.9% in Caribbean women to 3.9% in black African women. Prescription rates decreased with increasing social deprivation, from 24.2% in the most affluent to 10.9% in the most deprived groups. London had lower prescription rates (11.7%) than other regions (all >19%). Multivariable Cox regression showed that non-white ethnic groups had significantly lower HRT prescription rates (hazard ratios 0.85-0.92, P<0.001), and each increase in social deprivation group was associated with lower HRT prescription rates (hazard ratio for the most deprived group 0.92, 95% confidence interval 0.92 to 0.93, P<0.001). Conclusions: This study identified differences in HRT prescribing in England based on ethnic group, socioeconomic status, and geographical location. White women and those in more affluent neighbourhoods were more likely to receive HRT than non-white women and those in more deprived areas. These findings suggest potential inequities that require further exploration.
- Open Access
Vulval lichen sclerosus in UK general practice: a cross-sectional survey of patient experience
Objective To explore experience and prevalence of vulval lichen sclerosus (VLS) diagnosis in general practice using an anonymous patient survey. Design Quantitative descriptive cross-sectional survey informed by previous qualitative interviews and developed with patient representatives, sent to people recorded in general practice as having a VLS diagnosis. Setting General practices (n=24) in the UK (West Midlands). Participants n=177 respondents. Results One in five respondents reported that they had been misdiagnosed, and about a third reported that it was a struggle to get treatment. Only one third said they received regular check-ups, recommended in clinical guidelines. One-fifth reported they were not being treated with topical corticosteroids, the main first-line treatment for VLS. Less than one in 10 were members of a support group, and around four in 10 felt they had to hide their condition and did not speak to anyone else about it. Survey respondents prioritised improving education and awareness among healthcare professionals (HCPs). Conclusion General practitioners and other primary care HCPs have a key role in recognising, diagnosing and managing VLS. Improving education and awareness among HCPs was a key priority for this patient group. Patients should be made aware of the need for ongoing treatment and yearly check-ups to prevent or manage disease progression. VLS is a highly stigmatised condition, and appointments with HCPs may be the only opportunity for people to talk about their experience.
Open AccessVulval lichen sclerosus in UK general practice: a cross-sectional survey of patient experience
Objective To explore experience and prevalence of vulval lichen sclerosus (VLS) diagnosis in general practice using an anonymous patient survey. Design Quantitative descriptive cross-sectional survey informed by previous qualitative interviews and developed with patient representatives, sent to people recorded in general practice as having a VLS diagnosis. Setting General practices (n=24) in the UK (West Midlands). Participants n=177 respondents. Results One in five respondents reported that they had been misdiagnosed, and about a third reported that it was a struggle to get treatment. Only one third said they received regular check-ups, recommended in clinical guidelines. One-fifth reported they were not being treated with topical corticosteroids, the main first-line treatment for VLS. Less than one in 10 were members of a support group, and around four in 10 felt they had to hide their condition and did not speak to anyone else about it. Survey respondents prioritised improving education and awareness among healthcare professionals (HCPs). Conclusion General practitioners and other primary care HCPs have a key role in recognising, diagnosing and managing VLS. Improving education and awareness among HCPs was a key priority for this patient group. Patients should be made aware of the need for ongoing treatment and yearly check-ups to prevent or manage disease progression. VLS is a highly stigmatised condition, and appointments with HCPs may be the only opportunity for people to talk about their experience.
- Open Access
- 8 July 2025
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 75 (761) , e816-e823
Accessing equitable menopause care in the contemporary NHS: a qualitative study of women's experiences
Background: Women from lower socioeconomic status and minority ethnic backgrounds have earlier onset and more complex menopause symptoms. Hormone replacement therapy (HRT) has grown in popularity in recent years, however there are stark disparities in those who access HRT. Rates of use in deprived areas and for Black and Asian women are significantly lower than that of White women and those in more affluent areas. Aim: To explore women’s experiences of menopause and accessing primary care, as well as how perceptions and approaches may be shaped by cultural norms, to gain deeper understanding of factors shaping approaches to managing menopause and HRT prescribing patterns. Design & setting: Qualitative study with women recruited from general practice and community networks. Method: In-depth semi-structured interviews and focus groups with women experiencing menopause ( n = 40) were conducted between October 2023 and March 2024. Purposive sampling allowed a breadth of experiences and thematic analysis was conducted. Results: Three themes were developed in relation to women’s experiences of accessing menopause care: 1) ‘Contemporary contexts’ shaped women’s experiences; managing menopause alongside high workloads and caring responsibilities posed challenges perceived as distinct from previous generations; and there was heightened awareness, reduced stigma, and mixed views regarding HRT; 2) ‘How menopause care is experienced’ demonstrated how consultations about menopause were emotionally charged, many felt they would have to advocate for HRT (if they wanted it), and some felt frustrated with the lack of options available; and 3) ‘Cultural and economic background influences on menopause help seeking’ included how some women from Black or Asian backgrounds did not discuss menopause within their communities. Mistrust of medical institutions and treatments, as well as lack of representation, was problematic for Black and Asian participants. Some women worried about stereotyping during consultations. Conclusion: The findings outline how menopause may be particularly disruptive to modern women, demonstrate how women are often dissatisfied with the options available, and highlight key areas, such as communication about HRT benefits and/or risks, which could be improved in primary care settings.
- 8 July 2025
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 75 (761) , e816-e823
Open AccessAccessing equitable menopause care in the contemporary NHS: a qualitative study of women's experiences
Background: Women from lower socioeconomic status and minority ethnic backgrounds have earlier onset and more complex menopause symptoms. Hormone replacement therapy (HRT) has grown in popularity in recent years, however there are stark disparities in those who access HRT. Rates of use in deprived areas and for Black and Asian women are significantly lower than that of White women and those in more affluent areas. Aim: To explore women’s experiences of menopause and accessing primary care, as well as how perceptions and approaches may be shaped by cultural norms, to gain deeper understanding of factors shaping approaches to managing menopause and HRT prescribing patterns. Design & setting: Qualitative study with women recruited from general practice and community networks. Method: In-depth semi-structured interviews and focus groups with women experiencing menopause ( n = 40) were conducted between October 2023 and March 2024. Purposive sampling allowed a breadth of experiences and thematic analysis was conducted. Results: Three themes were developed in relation to women’s experiences of accessing menopause care: 1) ‘Contemporary contexts’ shaped women’s experiences; managing menopause alongside high workloads and caring responsibilities posed challenges perceived as distinct from previous generations; and there was heightened awareness, reduced stigma, and mixed views regarding HRT; 2) ‘How menopause care is experienced’ demonstrated how consultations about menopause were emotionally charged, many felt they would have to advocate for HRT (if they wanted it), and some felt frustrated with the lack of options available; and 3) ‘Cultural and economic background influences on menopause help seeking’ included how some women from Black or Asian backgrounds did not discuss menopause within their communities. Mistrust of medical institutions and treatments, as well as lack of representation, was problematic for Black and Asian participants. Some women worried about stereotyping during consultations. Conclusion: The findings outline how menopause may be particularly disruptive to modern women, demonstrate how women are often dissatisfied with the options available, and highlight key areas, such as communication about HRT benefits and/or risks, which could be improved in primary care settings.